ATE330973T1 - Antagonisten von g protein-gekoppelten rezeptoren - Google Patents

Antagonisten von g protein-gekoppelten rezeptoren

Info

Publication number
ATE330973T1
ATE330973T1 AT97943532T AT97943532T ATE330973T1 AT E330973 T1 ATE330973 T1 AT E330973T1 AT 97943532 T AT97943532 T AT 97943532T AT 97943532 T AT97943532 T AT 97943532T AT E330973 T1 ATE330973 T1 AT E330973T1
Authority
AT
Austria
Prior art keywords
protein
ccr3
methods
antagonists
chemokine receptor
Prior art date
Application number
AT97943532T
Other languages
English (en)
Inventor
Charles R Mackay
Paul D Ponath
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Application granted granted Critical
Publication of ATE330973T1 publication Critical patent/ATE330973T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT97943532T 1996-09-30 1997-09-24 Antagonisten von g protein-gekoppelten rezeptoren ATE330973T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/720,565 US6537764B1 (en) 1995-01-19 1996-09-30 Method of identifying inhibitors of C—C chemokine receptor 3

Publications (1)

Publication Number Publication Date
ATE330973T1 true ATE330973T1 (de) 2006-07-15

Family

ID=24894465

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97943532T ATE330973T1 (de) 1996-09-30 1997-09-24 Antagonisten von g protein-gekoppelten rezeptoren

Country Status (11)

Country Link
US (5) US6537764B1 (de)
EP (1) EP0932626B1 (de)
JP (1) JP2001524068A (de)
KR (1) KR20000048759A (de)
CN (1) CN1234806A (de)
AT (1) ATE330973T1 (de)
AU (1) AU734306C (de)
CA (1) CA2267190A1 (de)
DE (1) DE69736184D1 (de)
NZ (1) NZ334855A (de)
WO (1) WO1998014480A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537764B1 (en) * 1995-01-19 2003-03-25 Children's Medical Center Corporation Method of identifying inhibitors of C—C chemokine receptor 3
US6743594B1 (en) 1995-06-06 2004-06-01 Human Genome Sciences, Inc. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
US6025154A (en) 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
US6271347B1 (en) * 1996-04-26 2001-08-07 Merck & Co., Inc. Eosinophil eotaxin receptor
AU5241099A (en) * 1998-07-31 2000-02-21 Trustees Of Columbia University In The City Of New York, The Use of inhibitors of the activation of cxcr4 receptor by sdf-1 in treating rheumatoid arthritis
FR2783326B1 (fr) * 1998-09-10 2000-12-01 Immunotech Sa Procede de detection ou de quantification des basophiles et des eosinophiles
US6171590B1 (en) * 1998-09-30 2001-01-09 Corixa Corporation Chemokine receptor peptide for inducing an immune response
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
FR2830940B1 (fr) * 2001-10-17 2007-06-15 Commissariat Energie Atomique Procede de selection de ligands d'hla-dp4 et ses applications
US7253007B2 (en) * 2001-11-30 2007-08-07 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7871619B2 (en) * 2001-11-30 2011-01-18 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7442512B2 (en) * 2001-11-30 2008-10-28 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7413866B2 (en) * 2001-11-30 2008-08-19 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7393934B2 (en) 2001-12-21 2008-07-01 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
US8658773B2 (en) 2011-05-02 2014-02-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
US7649011B2 (en) 2002-12-20 2010-01-19 Chemocentryx, Inc. Inhibitors of human tumor-expressed CCXCKR2
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
US20100247540A1 (en) * 2003-10-30 2010-09-30 Chemocentryx, Inc. Methods and Compositions For Modulating Angiogenesis
JP2008507255A (ja) 2004-03-12 2008-03-13 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド ヒトｇタンパク質ケモカインレセプター（ｃｃｒ５）ｈｄｇｎｒ１０
US7309589B2 (en) 2004-08-20 2007-12-18 Vironix Llc Sensitive detection of bacteria by improved nested polymerase chain reaction targeting the 16S ribosomal RNA gene and identification of bacterial species by amplicon sequencing
PT1871804E (pt) * 2005-04-21 2013-10-31 Chemocentryx Inc Anticorpos que ligam ccx-ckr2
PT3903829T (pt) 2009-02-13 2023-06-02 Immunomedics Inc Imunoconjugados com uma ligação intracelular clivável
WO2011034660A1 (en) 2009-09-16 2011-03-24 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
ES2978177T3 (es) 2009-12-02 2024-09-06 Immunomedics Inc Combinación de radio inmunoterapia y conjugados anticuerpo-fármaco para mejorar la terapia contra el cáncer
AU2013302696B9 (en) 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
CA3177936A1 (en) 2012-12-13 2014-06-19 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
WO2015126548A1 (en) 2014-02-21 2015-08-27 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to trop-2 expressing cells
CN106029098A (zh) 2014-02-25 2016-10-12 免疫医疗公司 人源化rfb4抗cd22抗体
CN105462929B (zh) * 2014-06-13 2019-11-22 中国人民解放军军事医学科学院毒物药物研究所 一种筛选ccr4拮抗剂的细胞模型及筛选方法
US9580495B2 (en) 2014-06-24 2017-02-28 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
SI3204018T1 (sl) 2014-10-07 2021-11-30 Immunomedics, Inc. Neoadjuvantna uporaba konjugatov protitelo-zdravilo
WO2016172427A1 (en) 2015-04-22 2016-10-27 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
EP3313443B9 (de) 2015-06-25 2023-10-04 Immunomedics, Inc. Kombination von anti-hla-dr- oder anti-trop-2-antikörpern mit mikrotubuli-inhibitoren, parp-inhibitoren, bruton-kinase-inhibitoren oder phosphoinositol-3-kinase-inhibitoren zur signifikanten verbesserung des therapeutischen ergebnisses bei krebs
SI3316885T1 (sl) 2015-07-01 2021-09-30 Immunomedics, Inc. Imunokonjugati protitelo-SN-38 z linkerjem CL2A
CN112535681B (zh) * 2019-09-23 2024-01-23 华南理工大学 一种芳基硫酸酯酶和葡萄糖苷醛酸酶抑制剂及其制法和应用
ES2965266T3 (es) 2020-03-09 2024-04-11 Illumina Inc Métodos para la secuenciación de polinucleótidos
WO2022239720A1 (ja) 2021-05-10 2022-11-17 公益財団法人川崎市産業振興財団 抗原への結合親和性を低減させた抗体
CN117813396A (zh) 2021-12-16 2024-04-02 因美纳有限公司 混合聚类
US20240279733A1 (en) 2021-12-17 2024-08-22 Illumina, Inc. Orthogonal hybridization
US20240102067A1 (en) 2022-09-26 2024-03-28 Illumina, Inc. Resynthesis Kits and Methods
US20240124914A1 (en) 2022-09-30 2024-04-18 Illumina, Inc. Thermophilic compositions for nucleic acid amplification
US20240110234A1 (en) 2022-09-30 2024-04-04 Illumina, Inc. Amplification Compositions and Methods
US20240110221A1 (en) 2022-09-30 2024-04-04 Illumina, Inc. Methods of modulating clustering kinetics
US20240124929A1 (en) 2022-09-30 2024-04-18 Illumina, Inc. Mesophilic compositions for nucleic acid amplification
WO2025072683A1 (en) 2023-09-29 2025-04-03 Illumina, Inc. Solid supports and methods for strand invasion-based amplification
WO2025137479A1 (en) 2023-12-22 2025-06-26 Illumina, Inc. Reusable flow cells and methods of using them for nucleic acid sequencing

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470571A (en) * 1988-01-27 1995-11-28 The Wistar Institute Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5284746A (en) * 1990-02-08 1994-02-08 Zymogenetics, Inc. Methods of producing hybrid G protein-coupled receptors
US5462856A (en) * 1990-07-19 1995-10-31 Bunsen Rush Laboratories, Inc. Methods for identifying chemicals that act as agonists or antagonists for receptors and other proteins involved in signal transduction via pathways that utilize G-proteins
US5453491A (en) * 1990-09-11 1995-09-26 Kiyoshi Takatsu Murine interleukin-5 receptor
US5543503A (en) * 1991-03-29 1996-08-06 Genentech Inc. Antibodies to human IL-8 type A receptor
US5668006A (en) * 1992-07-17 1997-09-16 American Cyanamid Company Somatostatin receptors
US5508384A (en) * 1992-09-10 1996-04-16 New York University Polypeptide derived from a popamine receptor, and compositions and methods thereof
EP0669979B1 (de) * 1992-11-10 2005-10-12 Genentech, Inc. C-c ckr-1, ein c-c chemokin rezeptor
ES2118372T3 (es) * 1992-11-17 1998-09-16 Icos Corp Nuevos receptores siete transmembrana v28.
US5652133A (en) 1993-01-28 1997-07-29 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Cloning and expression of the human macrophage inflammatory protein-1.alpha.α) /rantes receptor
US5514555A (en) * 1993-03-12 1996-05-07 Center For Blood Research, Inc. Assays and therapeutic methods based on lymphocyte chemoattractants
DE4332256C1 (de) * 1993-09-22 1995-03-09 Lipp Martin Dr Dr Habil Monoklonale Antikörper gegen Leukozyten-spezifische G-Protein-gekoppelte Rezeptoren
ATE347594T1 (de) * 1994-01-13 2006-12-15 Univ California Monocyten protein rezeptoren aus säugern, mit chemoattraktion auslösender wirkung
EP0767796B1 (de) * 1994-05-16 2001-09-26 Human Genome Sciences, Inc. chemotaktisches protein
US6537764B1 (en) * 1995-01-19 2003-03-25 Children's Medical Center Corporation Method of identifying inhibitors of C—C chemokine receptor 3
US6806061B1 (en) 1995-01-19 2004-10-19 Children's Medical Center Corporation G protein-coupled receptor gene and methods of use therefor
US6512103B1 (en) 1995-12-08 2003-01-28 Schering Corporation Mammalian chemokine reagents
US6265184B1 (en) 1995-12-20 2001-07-24 Icos Corporation Polynucleotides encoding chemokine receptor 88C
US6271347B1 (en) * 1996-04-26 2001-08-07 Merck & Co., Inc. Eosinophil eotaxin receptor
CA2252850A1 (en) 1996-04-26 1997-11-06 Merck & Co., Inc. Eosinophil eotaxin receptor

Also Published As

Publication number Publication date
CA2267190A1 (en) 1998-04-09
DE69736184D1 (de) 2006-08-03
JP2001524068A (ja) 2001-11-27
NZ334855A (en) 2001-07-27
KR20000048759A (ko) 2000-07-25
EP0932626A1 (de) 1999-08-04
US6994977B2 (en) 2006-02-07
US20060002926A1 (en) 2006-01-05
EP0932626B1 (de) 2006-06-21
CN1234806A (zh) 1999-11-10
WO1998014480A1 (en) 1998-04-09
US20090068188A1 (en) 2009-03-12
US7402657B2 (en) 2008-07-22
US7012133B1 (en) 2006-03-14
AU4498397A (en) 1998-04-24
AU734306B2 (en) 2001-06-07
US20030143684A1 (en) 2003-07-31
US6537764B1 (en) 2003-03-25
AU734306C (en) 2002-03-21

Similar Documents

Publication Publication Date Title
DE69736184D1 (de) Antagonisten von g protein-gekoppelten rezeptoren
Getting et al. POMC gene-derived peptides activate melanocortin type 3 receptor on murine macrophages, suppress cytokine release, and inhibit neutrophil migration in acute experimental inflammation
Owen-Schaub et al. DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement
Taub et al. Alpha and β chemokines induce NK cell migration and enhance NK-mediated cytolysis
Rabin et al. Chemokine receptor responses on T cells are achieved through regulation of both receptor expression and signaling
Heinemann et al. Basophil responses to chemokines are regulated by both sequential and cooperative receptor signaling
DE69726878T2 (de) UNTERDRÜCKUNG VON TNFalpha UND IL-12 IN DER THERAPIE
Huang et al. Exposure to receptor-activator of NFκB ligand renders pre-osteoclasts resistant to IFN-γ by inducing terminal differentiation
DE69925024D1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
DE69532482D1 (de) Kombinationspräparat zur behandlung der parkinsonschen krankheit, das selektive nmda-antagonisten enthält
DK0714392T3 (da) Heterocykliske neurokinin-antagonister
WO1996022371A3 (en) C-C CHEMOKINE RECEPTOR 3: CKP-3 OR Eos-L2
EA200200194A1 (ru) Антагонисты хемокинного рецептора и способы их применения
US5545716A (en) Superantigen agonist and antagonist peptides
TR199901710T2 (xx) IL-8 resept�r antagonistleri.
BR9910144A (pt) Antagonistas de receptores de quimiocinas e seu uso
TR199900318T2 (xx) IL-8 resept�r antagonistleri.
NO943915L (no) Lymfocytt-aktiveringsantigen HB15, et medlem av immunoglobulin-superfamilien
Bianchi et al. Corticotropin releasing hormone, interleukin-1α, and tumor necrosis factor-α share characteristics of stress mediators
Schneider et al. Isolation of a biologically active macrophage receptor for the third component of complement
CA2152401A1 (fr) Association synergisante ayant un effet antagoniste des recepteurs nk1 et nk2
EA200000693A1 (ru) Антагонисты хемокинного рецептора и способы их применения
Wang et al. TLR3 ligand-induced accumulation of activated splenic natural killer cells into liver
DE69412662D1 (de) Angiotensin II-Antagonisten zur Behandlung von viralen Erkrankungen
EA200400692A1 (ru) Антагонисты хемокинного рецептора и способы их применения

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties